Preventing VTE recurrence

This is promotional content, intended for UK healthcare professionals only.
This webpage has been developed and funded by the Bristol-Myers Squibb / Pfizer Alliance.

Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.

This section addresses the long-term management of patients with VTE, which may involve:

Understanding the risk of VTE recurrence
Determining which patients may benefit from extended anticoagulation
Involving patients in the decision-making process
Evidence for the long-term prevention of VTE recurrence by anticoagulants

Adverse events should be reported. Reporting forms and information can be found via United Kingdom – The yellow card scheme at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (United Kingdom).

Previous
Next

In Preventing VTE recurrence: Preventing recurrence | Which patients may benefit from extended anticoagulation? | Evidence in long-term prevention of VTE recurrence |

Abbreviations

MHRA=Medicines and Healthcare products and Regulatory Agency VTE = Venous Thromboembolism

Job code: 432-GB-2100111

Date of preparation: September 2021

Managing and treating patients with VTE